Our deepest condolences to the Royal Family
Presentation at the DFSG 2022
We're so excited for exhibiting at the Diabetic Foot Study Group (DFSG) conference next week. Please be sure to visit us at booth no.11 where we will based during the conference. We welcome you to see our SteriPlas Cold Plasma medical device live in action.
We're also excited to announce that the Diabetes Team at Kettering General Hospital NHS Foundation Trust will have a poster presentation illustrating the strong antibacterial efficacy and healing qualities of the Adtec SteriPlas for diabetic foot ulcers.
The poster, "DGH EXPERIENCE OF USING COLD PLASMA MEDICAL DEVICE AS AN ADJUNCT THERAPY TO ANTIMICROBIALS IN TREATING CHRONIC NON HEALING INFECTED DIABETIC FOOT ULCERS" will be presented by Jemma Cruickshank on Saturday 17th September, 13:25 - 14:25.
See you all soon!
The ISHLT discusses the Cold Plasma Project
We’re ecstatic to see our Adtec SteriPlas continue to raise awareness in the LVAD community. A great interview between the ISHLT and Mr Thomas Schlöglhofer from the Medical University of Vienna discussing the benefits of our cold atmospheric plasma medical device for the treatment of LVAD Infections and their broad study being conducted.
Thomas has been an avid user of our medical device for some time now collecting remarkable results with his LVAD patients, documenting the strong benefits of our medical device including the significant reduction of infection rates coupled with full healing, reduction of readmittance and the stabilisation of LVAD systems all with the added benefit of no side effects.
We look forward to the completion of this study and the publishing of the data which will be discussed at the ISHLT 2023 conference next year. We will also be exhibiting at this conference and excited to meet more people from the LVAD community.
https://youtu.be/6-L0sgXLx9o
Antimicrobial (antibiotic) Resistance – the drugs won’t work !
Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year. WHO has declared that AMR is one of the top 10 global public health threats facing humanity.
(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.
SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections, diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported.
SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.
References
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
https://www.worldometers.info/coronavirus/
https://www.who.int/health-topics/antimicrobial-resistance
https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf
Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).
Diabetic Foot Study Group Conference
Are you excited as we are?
Looking forward to resuming exhibition season at the Diabetic Foot Study Group conference in Slovakia.
We'll be exhibiting between 16-18 Sept with our Adtec SteriPlas on demonstration ready to show you just how quick and effective it is to use and combat antibiotic resistant bacteria within diabetic foot ulcers.
EUMS-ISMCS 2022
We are overwhelmed by all the positive interactions we've had at the EUMS-ISMCS 2022 conference. Lots of you have taken a huge interest into our Cold Plasma SteriPlas medical device and its strong efficacy with LVAD infections. It's great to have seen regular faces as well as meeting new.
We hope you also got to see Dr Heinrich Rotering's presentation during the conference, "Treatment of Biofilm-Infested Implants - A Tissue Saving Approach". His great presentation elaborates the key benefits of using the SteriPlas for Sternal wound infections and LVAD infections.
Contact us for more info on info@adtecplasma.com
EWMA 2022
We're having a great time exhibiting at the European Wound Management Association (EWMA) conference. Today is the last day at the conference but we've already had an eventful start, welcoming you all to our booth to learn about the benefits of our Cold Plasma SteriPlas medical device.
Contact us at info@adtecplasma.com to learn more about the benefits we bring to wound healing.
Resuming the exhibition season of May 2022
We’re excited to resume our month of exhibitions. Starting from next week, you can find us at the EWMA conference in Paris from 23-25 May and at the EUMS-ISMCS conference in Hannover from 24-27 May. At both conferences, we will be exhibiting with our cold plasma medical device, the Adtec SteriPlas, ready to give you a live demonstration on how quick and effective it is for chronic infection management.
Be sure to visit us at booth no.270 at EWMA and booth no.24 at EUMS.
We would also like to encourage you to visit Dr Heinrich Rotering’s cold plasma presentation at EWMA, where he will be speaking about the efficacy of our medical device for cardiac surgical site infections. His poster presentation will be held at 10am on Tuesday 24th May 2022.
We’re looking forward to meeting with new and familiar faces next week. Stay tuned for our updates to follow.
Welcoming delegates at The Malvern Diabetic Foot conference
We’re having a great time welcoming you all to our booth at the Malvern Diabetic Foot Conference, introducing you all to the benefits of the SteriPlas cold plasma for the treatment of diabetic foot ulcers.
For those wishing to learn more about our clinical efficacy in diabetic foot ulcers, please contact us at info@adtecplasma.com for more information.
Welcoming Cardiothoracic Specialists at The SCTS
We're having a great time at the Society for Cardiothoracic Surgery in GB & Ireland conference, introducing the strong benefits of our Adtec SteriPlas cold plasma for deep sternal wound infections.
Please do pop by & see us at booth 18 to see our medical device in action.